CR20220141A - Derivados de 2-azaspiro[3,4]octano como agonistas de m4 - Google Patents
Derivados de 2-azaspiro[3,4]octano como agonistas de m4Info
- Publication number
- CR20220141A CR20220141A CR20220141A CR20220141A CR20220141A CR 20220141 A CR20220141 A CR 20220141A CR 20220141 A CR20220141 A CR 20220141A CR 20220141 A CR20220141 A CR 20220141A CR 20220141 A CR20220141 A CR 20220141A
- Authority
- CR
- Costa Rica
- Prior art keywords
- agonists
- azaspiro
- octane derivatives
- octane
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Abstract
En la presente se proporcionan compuestos de acuerdo con la Fórmula (I) o una sal farmacéuticamente aceptable de los mismos, en donde R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>5</sup>, y R<sup>7</sup> se definen en la presente. También se proporcionan en la presente composiciones farmacéuticas que comprenden un compuesto de Fórmula (I) así como también el uso de dichos compuestos como agonistas del receptor M4.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962912980P | 2019-10-09 | 2019-10-09 | |
PCT/IB2020/059430 WO2021070090A1 (en) | 2019-10-09 | 2020-10-07 | 2-azaspiro[3.4]octane derivatives as m4 agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20220141A true CR20220141A (es) | 2022-05-03 |
Family
ID=72944205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20220141A CR20220141A (es) | 2019-10-09 | 2020-10-07 | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 |
Country Status (21)
Country | Link |
---|---|
US (2) | US11548865B2 (es) |
EP (1) | EP4041389A1 (es) |
JP (1) | JP7349570B2 (es) |
KR (1) | KR20220079921A (es) |
CN (1) | CN114555592A (es) |
AR (1) | AR120170A1 (es) |
AU (1) | AU2020361735B2 (es) |
CA (1) | CA3156320A1 (es) |
CL (1) | CL2022000893A1 (es) |
CO (1) | CO2022004341A2 (es) |
CR (1) | CR20220141A (es) |
CU (1) | CU20220023A7 (es) |
EC (1) | ECSP22027287A (es) |
IL (1) | IL291316A (es) |
JO (1) | JOP20220082A1 (es) |
MX (1) | MX2022004213A (es) |
PE (1) | PE20221453A1 (es) |
TW (1) | TW202128649A (es) |
UY (1) | UY38906A (es) |
WO (1) | WO2021070090A1 (es) |
ZA (1) | ZA202202912B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20220082A1 (ar) * | 2019-10-09 | 2023-01-30 | Novartis Ag | مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 |
WO2024059249A1 (en) * | 2022-09-16 | 2024-03-21 | Cerevel Therapeutics, Llc | M4 activators/modulators and uses thereof |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060276520A1 (en) | 2002-11-13 | 2006-12-07 | Rigel Pharmaceuticals, Inc. | Rhodanine derivatives and pharmaceutical compositions containing them |
US7479496B2 (en) | 2004-02-19 | 2009-01-20 | Bristol-Myers Squibb Company | Substituted spiro azabicyclics as modulators of chemokine receptor activity |
WO2006006490A1 (ja) | 2004-07-08 | 2006-01-19 | Ono Pharmaceutical Co., Ltd. | スピロ化合物 |
EP1817032A2 (en) * | 2004-11-29 | 2007-08-15 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
JP5420408B2 (ja) | 2006-08-25 | 2014-02-19 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1型のインヒビター |
JP2012506883A (ja) | 2008-10-29 | 2012-03-22 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 置換されたスピロアミン |
BRPI1007350B8 (pt) | 2009-01-26 | 2021-05-25 | Israel Institute For Biological Res | compostos espiro heterocíclicos bicíclicos |
WO2012112743A1 (en) | 2011-02-18 | 2012-08-23 | Vertex Pharmaceuticals Incorporated | Chroman - spirocyclic piperidine amides as modulators of ion channels |
US9226923B2 (en) | 2011-07-27 | 2016-01-05 | Nanjing Allgen Pharma Co. Ltd. | Spirocyclic molecules as protein kinase inhibitors |
CA2881844A1 (en) | 2012-09-07 | 2014-03-13 | Zoetis Llc | Spirocyclic derivatives as antiparasitic agents |
SG11201501620QA (en) | 2012-09-18 | 2015-04-29 | Heptares Therapeutics Ltd | Bicyclic aza compounds as muscarinic m1 receptor agonists |
SG11201606269WA (en) * | 2014-02-06 | 2016-09-29 | Heptares Therapeutics Ltd | Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists |
CA2964103C (en) | 2014-10-31 | 2022-08-30 | Indivior Uk Limited | Dopamine d3 receptor antagonist compounds |
GB201504675D0 (en) * | 2015-03-19 | 2015-05-06 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201513740D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonist |
GB201513743D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
GB201513742D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
EP3805215A1 (en) | 2016-06-10 | 2021-04-14 | Vitae Pharmaceuticals, LLC | Inhibitors of the menin-mll interaction |
GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
CN108456208B (zh) | 2017-02-22 | 2021-04-16 | 广州市恒诺康医药科技有限公司 | 氮杂螺环类化合物及其制备方法和应用 |
EP3601249A4 (en) | 2017-03-24 | 2020-12-16 | Kura Oncology, Inc. | METHODS OF TREATMENT OF MALIGNANT HEMOPATHIES AND EWING'S SARCOMA |
GB201709652D0 (en) | 2017-06-16 | 2017-08-02 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
HUE061533T2 (hu) | 2018-03-23 | 2023-07-28 | Pfizer | Piperazin azaspiro származékok |
GB201810245D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
JOP20220082A1 (ar) * | 2019-10-09 | 2023-01-30 | Novartis Ag | مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 |
US11485742B2 (en) * | 2019-10-09 | 2022-11-01 | Novartis Ag | 2-azaspiro[3.4]octane derivatives as M4 agonists |
-
2020
- 2020-10-07 JO JOP/2022/0082A patent/JOP20220082A1/ar unknown
- 2020-10-07 CU CU2022000023A patent/CU20220023A7/es unknown
- 2020-10-07 EP EP20793460.5A patent/EP4041389A1/en active Pending
- 2020-10-07 UY UY0001038906A patent/UY38906A/es unknown
- 2020-10-07 MX MX2022004213A patent/MX2022004213A/es unknown
- 2020-10-07 TW TW109134714A patent/TW202128649A/zh unknown
- 2020-10-07 AR ARP200102775A patent/AR120170A1/es unknown
- 2020-10-07 CA CA3156320A patent/CA3156320A1/en active Pending
- 2020-10-07 JP JP2022521118A patent/JP7349570B2/ja active Active
- 2020-10-07 CR CR20220141A patent/CR20220141A/es unknown
- 2020-10-07 WO PCT/IB2020/059430 patent/WO2021070090A1/en active Application Filing
- 2020-10-07 PE PE2022000553A patent/PE20221453A1/es unknown
- 2020-10-07 AU AU2020361735A patent/AU2020361735B2/en active Active
- 2020-10-07 US US17/065,360 patent/US11548865B2/en active Active
- 2020-10-07 KR KR1020227015315A patent/KR20220079921A/ko unknown
- 2020-10-07 CN CN202080071012.7A patent/CN114555592A/zh active Pending
-
2022
- 2022-03-10 ZA ZA2022/02912A patent/ZA202202912B/en unknown
- 2022-03-13 IL IL291316A patent/IL291316A/en unknown
- 2022-04-05 CO CONC2022/0004341A patent/CO2022004341A2/es unknown
- 2022-04-06 EC ECSENADI202227287A patent/ECSP22027287A/es unknown
- 2022-04-07 CL CL2022000893A patent/CL2022000893A1/es unknown
- 2022-12-06 US US18/062,356 patent/US20230212139A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
ZA202202912B (en) | 2023-04-26 |
AU2020361735A1 (en) | 2022-04-21 |
CN114555592A (zh) | 2022-05-27 |
US11548865B2 (en) | 2023-01-10 |
EP4041389A1 (en) | 2022-08-17 |
MX2022004213A (es) | 2022-05-03 |
CU20220023A7 (es) | 2022-11-07 |
CL2022000893A1 (es) | 2023-01-20 |
JP2022552244A (ja) | 2022-12-15 |
AU2020361735B2 (en) | 2024-04-18 |
PE20221453A1 (es) | 2022-09-21 |
JP7349570B2 (ja) | 2023-09-22 |
CA3156320A1 (en) | 2021-04-15 |
IL291316A (en) | 2022-05-01 |
KR20220079921A (ko) | 2022-06-14 |
WO2021070090A1 (en) | 2021-04-15 |
UY38906A (es) | 2021-05-31 |
CO2022004341A2 (es) | 2022-04-29 |
AR120170A1 (es) | 2022-02-02 |
TW202128649A (zh) | 2021-08-01 |
ECSP22027287A (es) | 2022-12-30 |
US20210107889A1 (en) | 2021-04-15 |
JOP20220082A1 (ar) | 2023-01-30 |
US20230212139A1 (en) | 2023-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20220251A (es) | Nuevos derivados de metilquinazolinona | |
MX2021010314A (es) | Derivados de tiazol como inhibidores de la secreción de proteínas. | |
MX2021000093A (es) | Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos. | |
WO2019165043A3 (en) | Indane-amines as pd-l1 antagonists | |
ZA202201503B (en) | Urea compound for antagonizing lpa1 receptor | |
MX2020009530A (es) | Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa. | |
CR20220141A (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
CR20220153A (es) | Derivados de 2–azaespiro [3.4] octano como agonistas de m4 | |
WO2019207257A8 (fr) | Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices | |
MX2021012105A (es) | Compuestos de pirrol. | |
PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
PH12020551341A1 (en) | 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof | |
CR20210173A (es) | Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
MX2022004144A (es) | Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3. | |
WO2020102053A8 (en) | Methods of preparing cytotoxic benzodiazepine derivatives | |
WO2021026479A9 (en) | Small molecule inhibitors of s1p2 receptor and uses thereof | |
WO2020139971A3 (en) | Methods for making dimeric naphthalimides and solid state forms of the same | |
CR20210181A (es) | Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa | |
BR112022008647A2 (pt) | Composto de imidazolidinona, método de preparação do mesmo e uso do mesmo | |
PH12021550248A1 (en) | Borate of azetidine derivative | |
MX2022002941A (es) | Cristal de derivado de 1,3,5-triazina o solvato del mismo y metodo para producir el mismo. | |
MX2022004178A (es) | Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3. | |
MX2021014458A (es) | Compuestos triciclicos. | |
MX2021002260A (es) | Compuestos utiles como moduladores de la autofagia mediada por chaperonas. | |
MX2022006776A (es) | Composiciones farmaceuticas oftalmicas. |